سعر تارسيفا 150مجم 30 قرص 2026

Erlotinib 150 mg film-coated tablets, pack of 30, by F. Hoffmann-La Roche > Multipharma; EGFR tyrosine kinase inhibitor antineoplastic.

• Metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (first-line, maintenance, or after prior chemotherapy).Population: AdultsDailyMed (U.S. National Library of Medicine)
• First-line treatment of locally advanced, unresectable or metastatic pancreatic cancer in combination with gemcitabine.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions are rash (70%) and diarrhoea (42%), usually starting in the first month.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• None (US label).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Interstitial lung disease (including fatal cases): withhold for new or progressive unexplained pulmonary symptoms; discontinue if ILD is confirmed.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Renal failure and hepatorenal syndrome, hepatotoxicity (including fatal hepatic failure), gastrointestinal perforation and bullous/exfoliative skin disorders can occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Embryo-fetal toxicity: females of reproductive potential should use effective contraception during treatment and for one month after the last dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inhibitors / combined CYP3A4-CYP1A2 inhibitors (e.g. ketoconazole, clarithromycin, ciprofloxacin, grapefruit)Increase erlotinib exposure; avoid, or reduce the erlotinib dose if unavoidable.DailyMed (U.S. National Library of Medicine)
• Cigarette smoking (CYP1A2 induction)Smoking decreases erlotinib exposure; avoid smoking.DailyMed (U.S. National Library of Medicine)

• Based on animal data and mechanism of action, erlotinib can cause fetal harm; advise pregnant women of the potential risk.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Do not breastfeed during treatment and for 2 weeks after the final dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Erlotinib: Kinase inhibitor of EGFR (HER1) used in EGFR-mutation-positive NSCLC (US label).